LINC00967: A Potential Drug Target and Biomarker (G100505659)

Target Name: LINC00967

NCBI ID: G100505659

LINC00967

Other Name(s): Long intergenic non-protein coding RNA 967 | long intergenic non-protein coding RNA 967

LINC00967: A Potential Drug Target and Biomarker

LINC00967 is a novel non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a long non-coding RNA molecule that is expressed in various tissues and cell types, including brain, heart, liver, and muscle. LINC00967 has been shown to play a role in the regulation of gene expression and has been associated with a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The search for potential drug targets and biomarkers is an ongoing process in the field of drug development. These targets can be identified through various methods, including screening approaches, such as high-throughput screening assays, gene expression profiling, and bioinformatics analysis. Once a potential target is identified, further studies are conducted to determine its feasibility as a drug target and to develop biomarkers that can be used to monitor its effectiveness.

LINC00967 as a Potential Drug Target

LINC00967 has been shown to be a potential drug target by its ability to interact with several protein molecules, including the transcription factor NF-kappa-B. NF-kappa-B is a protein that plays a role in the regulation of gene expression and is known to be involved in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

LINC00967 has been shown to interact with the NF-kappa-B protein by binding to its nuclear localization domain, which is responsible for the regulation of gene expression. This interaction between LINC00967 and NF-kappa-B has led to the conclusion that LINC00967 may be a useful drug target for the treatment of diseases that are characterized by the over-expression of NF-kappa-B.

LINC00967 as a Biomarker

In addition to its potential as a drug target, LINC00967 has also been shown to be a potential biomarker for a number of diseases. For example, LINC00967 has been shown to be over-expressed in a variety of cancer tissues and has been associated with the development of cancer. This suggests that LINC00967 may be a useful biomarker for the detection and prognosis of cancer.

LINC00967 has also been shown to be over-expressed in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that LINC00967 may be a useful biomarker for the detection and progression of these diseases.

LINC00967 has also been shown to be over-expressed in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. This suggests that LINC00967 may be a useful biomarker for the diagnosis and treatment of these disorders.

Conclusion

In conclusion, LINC00967 is a novel non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its interaction with the transcription factor NF-kappa-B and its over-expression in various tissues and diseases make it a promising candidate for further study. Further studies are needed to determine its feasibility as a drug target and to develop biomarkers that can be used to monitor its effectiveness.

Protein Name: Long Intergenic Non-protein Coding RNA 967

The "LINC00967 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00967 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets